Yildiz Mustafa
Medical Faculty, Department of Biophysics, Trakya University, 22030 Edirne, Türkiye.
Rev Cardiovasc Med. 2025 Jul 30;26(7):38696. doi: 10.31083/RCM38696. eCollection 2025 Jul.
Heart diseases (HDs) continue to be among the major diseases that adversely affect human health worldwide, with complex interactions between genetic, environmental, and biochemical factors contributing to their progression. These include coronary heart disease, hypertension, heart failure, vascular calcification, etc. Cardiovascular diseases have been extensively studied in the Framingham Heart Study since 1948, spanning three generations over the past 70 years, and are highly correlated with various factors, including biochemical, environmental, behavioral, and genetic factors. In recent years, epigenetic mechanisms have emerged as crucial regulators of cardiovascular pathology, influencing gene expression without altering the underlying DNA sequence. Moreover, early detection and diagnosis of heart diseases are crucial for improving treatment and prognosis. Recent studies on heart disease have found that the expression of potential candidate genes related to the disease is associated with epigenetic mechanisms. Indeed, abnormal methylation states have been detected in candidate genes that can serve as biomarkers to assess the progression of heart disease. Recent advances in next-generation sequencing techniques have contributed significantly to our understanding of heart diseases, including the role of DNA methylation, adenosine triphosphate (ATP)-dependent chromatin conformation and remodeling, post-translational modifications of histones and non-coding RNAs. Lastly, this review examines the latest discoveries in the epigenetic regulation of heart diseases, highlighting the roles of DNA methyltransferases (DNMTs), histone deacetylases (HDACs), sirtuins (SIRTs), and ten-eleven translocation proteins (TETs). Additionally, this review highlights preclinical therapeutic strategies targeting epigenetic modifiers, offering new avenues for precision medicine in cardiology. Understanding these epigenetic pathways is crucial for developing novel biomarkers and epigenetic-based therapies that aim to reverse maladaptive cardiac remodeling and enhance clinical outcomes.
心脏病仍然是全球范围内对人类健康产生不利影响的主要疾病之一,遗传、环境和生化因素之间复杂的相互作用促使其病情发展。这些疾病包括冠心病、高血压、心力衰竭、血管钙化等。自1948年以来,心血管疾病在弗雷明汉心脏研究中得到了广泛研究,在过去70年中涵盖了三代人,并且与各种因素高度相关,包括生化、环境、行为和遗传因素。近年来,表观遗传机制已成为心血管病理学的关键调节因子,在不改变基础DNA序列的情况下影响基因表达。此外,心脏病的早期检测和诊断对于改善治疗和预后至关重要。最近关于心脏病的研究发现,与该疾病相关的潜在候选基因的表达与表观遗传机制有关。事实上,在可作为评估心脏病进展生物标志物的候选基因中已检测到异常甲基化状态。下一代测序技术的最新进展极大地促进了我们对心脏病的理解,包括DNA甲基化、三磷酸腺苷(ATP)依赖性染色质构象和重塑、组蛋白的翻译后修饰以及非编码RNA的作用。最后,本综述探讨了心脏病表观遗传调控的最新发现,强调了DNA甲基转移酶(DNMTs)、组蛋白脱乙酰酶(HDACs)、沉默调节蛋白(SIRTs)和10-11易位蛋白(TETs)的作用。此外,本综述强调了针对表观遗传修饰剂的临床前治疗策略,为心脏病精准医学提供了新途径。了解这些表观遗传途径对于开发旨在逆转适应性不良心脏重塑并改善临床结果的新型生物标志物和基于表观遗传的疗法至关重要。
Rev Cardiovasc Med. 2025-7-30
Psychopharmacol Bull. 2024-7-8
Encephale. 2017-8
Epigenomics. 2025-7-22
Epigenomics. 2025-4
Cell Biol Toxicol. 2025-7-15
Curr Environ Health Rep. 2025-1-20
2025-1
Int J Cardiol Cardiovasc Risk Prev. 2024-12-6
Int J Mol Sci. 2024-6-4